Clover Health Hits Analysts’ Mark: What’s Next for Investors?
Recently, shares of Clover Health Investments Corp (Symbol: CLOV) traded at $3.28, surpassing the average analyst 12-month target price of $3.23. When a stock meets the target set by analysts, they have two potential paths: either downgrade the stock due to valuation or adjust their target prices higher. Analysts’ reactions often hinge on the underlying business developments fueling this price increase—if the company’s outlook improves, a revised target may be warranted.
Diverse Analyst Opinions on Target Prices
Three analysts contribute to the average target for Clover Health Investments Corp, which is an aggregate of their expectations. However, this average can mask significant variances; one analyst expects a price drop to $1.00, while another sets a high target of $4.50, resulting in a standard deviation of $1.939.
Market Reaction: Time for Investor Reflection
The average price target serves as a measure of collective analyst sentiment, helping investors gauge whether CLOV’s current price is a stepping stone toward further gains or a signal to consider selling. With CLOV exceeding the $3.23 target, it’s a prime moment for investors to reassess the company’s prospects and decide on their strategies.
| CLOV Analyst Ratings Overview | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Month Ago | 3 Month Ago |
| Strong buy ratings: | 1 | 1 | 1 | 1 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 2 | 2 | 2 | 2 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 2.33 | 2.33 | 2.33 | 2.33 |
The average rating shown in the table ranges from 1 (Strong Buy) to 5 (Strong Sell). This article utilized data from Zacks Investment Research via Quandl.com. Stay informed with the latest Zacks research report on CLOV — available for free.
10 ETFs With Most Upside To Analyst Targets »
Also see:
— WMC Split History
— APPN Stock Predictions
— CYTX Historical Stock Prices
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
